These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10072681)

  • 1. Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines.
    Chorvat RJ; Bakthavatchalam R; Beck JP; Gilligan PJ; Wilde RG; Cocuzza AJ; Hobbs FW; Cheeseman RS; Curry M; Rescinito JP; Krenitsky P; Chidester D; Yarem JA; Klaczkiewicz JD; Hodge CN; Aldrich PE; Wasserman ZR; Fernandez CH; Zaczek R; Fitzgerald LW; Huang SM; Shen HL; Wong YN; Chien BM; Arvanitis A
    J Med Chem; 1999 Mar; 42(5):833-48. PubMed ID: 10072681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines.
    Arvanitis AG; Gilligan PJ; Chorvat RJ; Cheeseman RS; Christos TE; Bakthavatchalam R; Beck JP; Cocuzza AJ; Hobbs FW; Wilde RG; Arnold C; Chidester D; Curry M; He L; Hollis A; Klaczkiewicz J; Krenitsky PJ; Rescinito JP; Scholfield E; Culp S; De Souza EB; Fitzgerald L; Grigoriadis D; Tam SW; Shen HL
    J Med Chem; 1999 Mar; 42(5):805-18. PubMed ID: 10072679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonists.
    Dzierba CD; Takvorian AG; Rafalski M; Kasireddy-Polam P; Wong H; Molski TF; Zhang G; Li YW; Lelas S; Peng Y; McElroy JF; Zaczek RC; Taub RA; Combs AP; Gilligan PJ; Trainor GL
    J Med Chem; 2004 Nov; 47(23):5783-90. PubMed ID: 15509177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
    Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
    J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligands.
    Hartz RA; Arvanitis AG; Arnold C; Rescinito JP; Hung KL; Zhang G; Wong H; Langley DR; Gilligan PJ; Trainor GL
    Bioorg Med Chem Lett; 2006 Feb; 16(4):934-7. PubMed ID: 16297619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and SAR of 2-aryloxy-4-alkoxy-pyridines as potent orally active corticotropin-releasing factor 1 receptor antagonists.
    Chen YL; Braselton J; Forman J; Gallaschun RJ; Mansbach R; Schmidt AW; Seeger TF; Sprouse JS; Tingley FD; Winston E; Schulz DW
    J Med Chem; 2008 Mar; 51(5):1377-84. PubMed ID: 18260619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imidazo[4,5-c]pyridines as corticotropin releasing factor receptor ligands.
    Arvanitis AG; Rescinito JT; Arnold CR; Wilde RG; Fitzgerald LW; Zaczek R; Hartig PR; Grossman S; Arneric SP; Gilligan PJ; Olson RE; Robertson DW
    Bioorg Med Chem Lett; 2003 Jan; 13(1):129-31. PubMed ID: 12467632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist.
    Hartz RA; Ahuja VT; Zhuo X; Mattson RJ; Denhart DJ; Deskus JA; Vrudhula VM; Pan S; Ditta JL; Shu YZ; Grace JE; Lentz KA; Lelas S; Li YW; Molski TF; Krishnananthan S; Wong H; Qian-Cutrone J; Schartman R; Denton R; Lodge NJ; Zaczek R; Macor JE; Bronson JJ
    J Med Chem; 2009 Dec; 52(23):7653-68. PubMed ID: 19954247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
    Gilligan PJ; Clarke T; He L; Lelas S; Li YW; Heman K; Fitzgerald L; Miller K; Zhang G; Marshall A; Krause C; McElroy JF; Ward K; Zeller K; Wong H; Bai S; Saye J; Grossman S; Zaczek R; Arneric SP; Hartig P; Robertson D; Trainor G
    J Med Chem; 2009 May; 52(9):3084-92. PubMed ID: 19361209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticotropin-releasing hormone receptor antagonists: framework design and synthesis guided by ligand conformational studies.
    Hodge CN; Aldrich PE; Wasserman ZR; Fernandez CH; Nemeth GA; Arvanitis A; Cheeseman RS; Chorvat RJ; Ciganek E; Christos TE; Gilligan PJ; Krenitsky P; Scholfield E; Strucely P
    J Med Chem; 1999 Mar; 42(5):819-32. PubMed ID: 10072680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational design, synthesis, and structure-activity relationships of aryltriazoles as novel corticotropin-releasing factor-1 receptor antagonists.
    Lowe RF; Nelson J; Dang TN; Crowe PD; Pahuja A; McCarthy JR; Grigoriadis DE; Conlon P; Saunders J; Chen C; Szabo T; Chen TK; Bozigian H
    J Med Chem; 2005 Mar; 48(5):1540-9. PubMed ID: 15743196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists.
    Guo Z; Tellew JE; Gross RS; Dyck B; Grey J; Haddach M; Kiankarimi M; Lanier M; Li BF; Luo Z; McCarthy JR; Moorjani M; Saunders J; Sullivan R; Zhang X; Zamani-Kord S; Grigoriadis DE; Crowe PD; Chen TK; Williams JP
    J Med Chem; 2005 Aug; 48(16):5104-7. PubMed ID: 16078829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclopenta[d]pyrimidines and dihydropyrrolo[2,3-d]pyrimidines as potent and selective corticotropin-releasing factor 1 receptor antagonists.
    Arban R; Benedetti R; Bonanomi G; Capelli AM; Castiglioni E; Contini S; Degiorgis F; Di Felice P; Donati D; Fazzolari E; Gentile G; Marchionni C; Marchioro C; Messina F; Micheli F; Oliosi B; Pavone F; Pasquarello A; Perini B; Rinaldi M; Sabbatini FM; Vitulli G; Zarantonello P; Di Fabio R; St-Denis Y
    ChemMedChem; 2007 Apr; 2(4):528-40. PubMed ID: 17335099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist.
    Chen YL; Mansbach RS; Winter SM; Brooks E; Collins J; Corman ML; Dunaiskis AR; Faraci WS; Gallaschun RJ; Schmidt A; Schulz DW
    J Med Chem; 1997 May; 40(11):1749-54. PubMed ID: 9171885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterization of a novel nonpeptide antagonist radioligand, (+/-)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for corticotropin-releasing factor1 receptors.
    Zhang G; Huang N; Li YW; Qi X; Marshall AP; Yan XX; Hill G; Rominger C; Prakash SR; Bakthavatchalam R; Rominger DH; Gilligan PJ; Zaczek R
    J Pharmacol Exp Ther; 2003 Apr; 305(1):57-69. PubMed ID: 12649353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of benzoylpyrimidines as antagonists of the corticotropin-releasing factor-1 receptor.
    Webb TR; Moran T; Huang CQ; McCarthy JR; Grigoriadis DE; Chen C
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3869-73. PubMed ID: 15225687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.
    Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Nakazato A; Kumagai T; Okubo T; Tomisawa K
    J Pharmacol Exp Ther; 1999 May; 289(2):926-35. PubMed ID: 10215672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core.
    Dyck B; Grigoriadis DE; Gross RS; Guo Z; Haddach M; Marinkovic D; McCarthy JR; Moorjani M; Regan CF; Saunders J; Schwaebe MK; Szabo T; Williams JP; Zhang X; Bozigian H; Chen TK
    J Med Chem; 2005 Jun; 48(12):4100-10. PubMed ID: 15943483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists.
    Gross RS; Guo Z; Dyck B; Coon T; Huang CQ; Lowe RF; Marinkovic D; Moorjani M; Nelson J; Zamani-Kord S; Grigoriadis DE; Hoare SR; Crowe PD; Bu JH; Haddach M; McCarthy J; Saunders J; Sullivan R; Chen T; Williams JP
    J Med Chem; 2005 Sep; 48(18):5780-93. PubMed ID: 16134945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Arylpyrimidines: novel CRF-1 receptor antagonists.
    Yoon T; De Lombaert S; Brodbeck R; Gulianello M; Krause JE; Hutchison A; Horvath RF; Ge P; Kehne J; Hoffman D; Chandrasekhar J; Doller D; Hodgetts KJ
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4486-90. PubMed ID: 18672365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.